2. Search Result
Search Result
Results for "

PAMP

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

8

Biochemical Assay Reagents

10

Peptides

2

Natural
Products

1

Recombinant Proteins

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2198
    PAMP-12(human, porcine)

    		Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    PAMP-12(human, porcine) is a major component of immunoreactive (ir)-PAMP, is processed from the adrenomedullin precursor, is a potent hypotensive peptide and participates in cardiovascular control .
    PAMP-12(human, porcine)
  • HY-P3419
    PAMP-12 (unmodified)
    1 Publications Verification

    		 Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    PAMP-12 (unmodified) is a potent MRGPRX2 (MrgX2) agonist (EC50=20-50 nM). PAMP-12 (unmodified) is an endogenous peptide that elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells .
    PAMP-12 (unmodified)
  • HY-P1831
    Proadrenomedullin (1-20), human

    ProAM N20, Human; PAMP-20, human

    		 nAChR Neurological Disease
    Proadrenomedullin (1-20), human is a potent hypotensive and catecholamine release–inhibitory peptide released from chromaffin cells with an IC50 of ~350 nM for catecholamine secretion in PC12 pheochromocytoma cells, acting in a noncompetitive manner specifically at the nicotinic cholinergic receptor .
    Proadrenomedullin (1-20), human
  • HY-RS00386
    ADM Human Pre-designed siRNA Set A

    AM; PAMP

    		 Small Interfering RNA (siRNA) Others

    ADM Human Pre-designed siRNA Set A contains three designed siRNAs for ADM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ADM Human Pre-designed siRNA Set A
    ADM Human Pre-designed siRNA Set A
  • HY-RS15929
    YME1L1 Human Pre-designed siRNA Set A

    FTSH; MEG4; PAMP; OPA11; YME1L

    		 Small Interfering RNA (siRNA) Others

    YME1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for YME1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YME1L1 Human Pre-designed siRNA Set A
    YME1L1 Human Pre-designed siRNA Set A
  • HY-P2198A
    PAMP-12(human, porcine) TFA

    		Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    PAMP-12(human, porcine) TFA is a major component of immunoreactive (ir)-PAMP, is processed from the adrenomedullin precursor, is a potent hypotensive peptide and participates in cardiovascular control .
    PAMP-12(human, porcine) TFA
  • HY-P3419A
    PAMP-12 (unmodified) (TFA)

    		Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease
    PAMP-12 (unmodified) TFA is a potent MRGPRX2 (MrgX2) agonist (EC50=20-50 nM). PAMP-12 (unmodified) is an endogenous peptide that elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells .
    PAMP-12 (unmodified) (TFA)
  • HY-P5876
    Proadrenomedullin (N-20) (bovine, porcine)

    ProADM N20(bovine, porcine); PAMP-20(bovine, porcine)

    		 nAChR Neurological Disease
    Proadrenomedullin (N-20) (ProADM N20) (bovine, porcine) is a potent and noncompetitive hypotensive and catecholamine release-inhibitory peptide released from chromaffin cells. Proadrenomedullin (N-20) (bovine, porcine) inhibits catecholamine secretion with an IC50 of 350 nM in PC12 pheochromocytoma cells. Proadrenomedullin (N-20) (bovine, porcine) also blocks (EC50≈270 nM) nicotinic cholinergic agonist desensitization of catecholamine release, as well as desensitization of nicotinic signal transduction ( 22Na + uptake) .
    Proadrenomedullin (N-20) (bovine, porcine)
  • HY-N3914
    Futoenone

    		Others Others
    Futoenone is a lignan, which can be isolated from Magnolia sprengeri Pamp .
    Futoenone
  • HY-145870
    Anti-inflammatory agent 13

    		NO Synthase Inflammation/Immunology
    Anti-inflammatory agent 13 (Compound 3) is a pentacyclic triterpene compound. Anti-inflammatory agent 13 exhibits a considerable inhibitory effect on inflammation models. Anti-inflammatory agent 13 has the potential for the research of either DAMPs or PAMPs triggered inflammation .
    Anti-inflammatory agent 13
  • HY-P2076
    Dusquetide

    SGX942

    		 p62 Bacterial Infection Cancer
    Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
    Dusquetide
  • HY-P2076A
    Dusquetide TFA

    SGX942 TFA

    		 p62 Bacterial Infection Cancer
    Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
    Dusquetide TFA
  • HY-N5101
    Kobusin

    		CFTR Chloride Channel Neurological Disease Inflammation/Immunology
    Kobusin is a bisepoxylignan isolated from the Pnonobio biondii Pamp. Kobusin is an activator of CFTR and CaCCgie chloride channels and a inhibitor of ANO1/CaCC (calcium-activated chloride channel) channel .
    Kobusin
  • HY-P10779
    flg22Pst

    		Bacterial Inflammation/Immunology
    flg22Pst is a peptide that can be derived Pseudomonas syringae pv. tabaci and serves as an effective elicitor for the plant immune system. flg22Pst can induce callose deposition in plants, trigger plant immune responses, and thereby assist plants in defending against pathogen invasion .
    flg22Pst
  • HY-D1056B4
    Lipopolysaccharides, from Salmonella typhosa

    LPS, from bacterial (Salmonella typhosa)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from Salmonella typhosa are lipopolysaccharide endotoxins and TLR-4 activators derived from Salmonella typhosa, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Salmonella typhosa exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Salmonella typhosa can serve as vaccine adjuvants and demonstrate adjuvant activity targeting B cells in immune responses in vivo .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from Salmonella typhosa
  • HY-D1056C1
    Lipopolysaccharides, from S. enterica serotype enteritidis

    LPS, from Salmonella enterica (Serotype enteritidis)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from S. enterica serotype enteritidis
  • HY-D1056C4
    Lipopolysaccharides, from S. enterica serotype abortus equi

    LPS, from Salmonella enterica (Serotype abortus equi)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype Abortusequi are lipopolysaccharide endotoxins and TLR-4 activators derived from the Abortusequi serotype of S. enterica, classified as a mutated R-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype abortus equi consist of core oligosaccharide (core oligosaccharide) and lipid A (Lipid A). S. enterica serotype Abortusequi is a major pathogen causing abortion in mares and is also associated with neonatal sepsis, multiple abscesses, orchitis, and polyarthritis in equids. It is primarily grouped based on lipopolysaccharides (O-antigen) and flagellin (H-antigen) .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from S. enterica serotype abortus equi
  • HY-D1056B2
    Lipopolysaccharides, from Proteus mirabilis

    LPS, from bacterial (Proteus mirabilis)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from Proteus mirabilis
  • HY-D1056B1
    Lipopolysaccharides, from Proteus vulgaris

    LPS, from bacterial (Proteus vulgaris)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from Proteus vulgaris are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus vulgaris, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus vulgaris exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Proteus vulgaris possess a unique molecular structure and chitosan affinity (Kb=2.72 μM), surpassing that of Yersinia pseudotuberculosis (Kb=6.06 μM) and Escherichia coli (Kb=79.50 μM) .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from Proteus vulgaris
  • HY-D1056H
    Lipopolysaccharides, from S. marcescens
    1 Publications Verification

    LPS, from Serratia marcescens

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from S. marcescens (Serratia marcescens) are lipopolysaccharide endotoxins and TLR-4 activators derived from Serratia marcescens, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. marcescens exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from S. marcescens induce NF-κB activation in mouse cells via Toll-like receptor (TLR4)/MD-2. The lipopolysaccharides of S. marcescens can induce apoptosis in host immune cells, thereby suppressing the host's innate immunity .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from S. marcescens
  • HY-D1056A5
    Lipopolysaccharides, from E. coli K-235

    LPS, from Escherichia coli (K-235)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli (Escherichia coli) K-235 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli K-235 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from E. coli K-235 have a mitogenic effect on C57BL/10ScN spleen cells. Additionally, LPS purified using butanol and deoxycholic acid methods stimulates spleen cells in C57BL/10ScCR and C3H/HeJ mice .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from E. coli K-235
  • HY-D1056A3
    Lipopolysaccharides, from E. coli O26:B6

    LPS, from Escherichia coli (O26:B6)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A), and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be blocked by PD149163 (HY-123434) .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from E. coli O26:B6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: